Arcadia Biosciences マネジメント

マネジメント基準チェック /24

現在、CEO に関する十分な情報がありません。

主要情報

Thomas Schaefer

最高経営責任者

US$381.8k

報酬総額

CEO給与比率	68.1%
CEO在任期間	2.3yrs
CEOの所有権	0.2%
経営陣の平均在職期間	データなし
取締役会の平均在任期間	6.5yrs

経営陣の近況

Recent updates

We Think Shareholders Should Be Aware Of Some Factors Beyond Arcadia Biosciences' (NASDAQ:RKDA) Profit

Nov 22

The Future Looks Bright For Arcadia Biosciences

Dec 01

Arcadia Biosciences EPS misses by $0.06

Nov 12

CEO報酬分析

Arcadia Biosciences の収益と比較して、Thomas Schaefer の報酬はどのように変化したか？
日付	総報酬	給与	会社業績
Sep 30 2024	n/a	n/a	-US$9m
Jun 30 2024	n/a	n/a	-US$8m
Mar 31 2024	n/a	n/a	-US$6m
Dec 31 2023	US$382k	US$260k	-US$13m

報酬と市場: Thomasの総報酬 ($USD 381.84K ) は、 US市場 ($USD 649.63K ) の同様の規模の企業の平均を下回っています。

報酬と収益: Thomasの報酬と会社の業績を比較するにはデータが不十分です。

CEO（最高経営責任者

Thomas Schaefer (48 yo)

2.3yrs

在職期間

US$381,838

報酬

Mr. Thomas J. Schaefer serves as Chief Executive Officer and President of Arcadia Biosciences, Inc. from July 05, 2024 and is its Director since August 1, 2024. He served as Chief Financial Officer of Arca...

取締役

名称	ポジション	在職期間	報酬	所有権
Thomas Schaefer	CEO, President & Director	less than a year	US$381.84k	0.16% $ 5.8k
Gregory Waller	Independent Director	7.4yrs	US$68.32k	0% $ 0
Lilian Murray	Independent Director	6.4yrs	US$68.32k	0.016% $ 586.3
Albert Bolles	Independent Director	6.5yrs	US$50.32k	0% $ 0
Kevin Comcowich	Independent Chair of the Board	8.1yrs	US$99.09k	0.037% $ 1.4k
Amy Yoder	Independent Director	7.3yrs	US$64.82k	0% $ 0
Deborah Carosella	Independent Director	3.8yrs	US$57.48k	0% $ 0

6.5yrs

平均在職期間

65yo

平均年齢

経験豊富なボード: RKDAの取締役会は経験豊富であると考えられます ( 6.5年の平均在任期間)。

Arcadia Biosciences マネジメント

マネジメント 基準チェック /24

主要情報

経営陣の近況

Arcadia Biosciences, Inc. Announces Appointment of Mark Kawakami, as Chief Financial Officer

Arcadia Biosciences, Inc., Annual General Meeting, Jun 25, 2024

Insufficient new directors

Arcadia Biosciences, Inc. Announces the Resignation of Laura Pitlik as Chief Marketing Officer

Arcadia Biosciences, Inc. Announces CFO Changes

Arcadia Biosciences, Inc., Annual General Meeting, Jun 01, 2022

Recent updates

Consensus EPS estimates upgraded to US$1.10 loss, revenue downgraded

New major risk - Share price stability

Third quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Arcadia Biosciences, Inc. to Report Q3, 2024 Results on Nov 12, 2024

Consensus EPS estimates fall by 27%, revenue upgraded

Consensus estimates of losses per share improve by 17%

Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Arcadia Biosciences, Inc. to Report Q2, 2024 Results on Aug 13, 2024

Arcadia Biosciences, Inc. Announces Appointment of Mark Kawakami, as Chief Financial Officer

Consensus revenue estimates decrease by 17%, EPS upgraded

Arcadia Biosciences, Inc., Annual General Meeting, Jun 25, 2024

First quarter 2024 earnings released: US$1.78 loss per share (vs US$10.86 loss in 1Q 2023)

First quarter 2024 earnings released: US$1.78 loss per share (vs US$10.86 loss in 1Q 2023)

Arcadia Biosciences, Inc. to Report Q1, 2024 Results on May 09, 2024

Consensus revenue estimates fall by 27%

Full year 2023 earnings: EPS and revenues miss analyst expectations

Arcadia Biosciences, Inc. to Report Q4, 2023 Results on Mar 28, 2024

Insufficient new directors

Arcadia Biosciences, Inc. (Rkda) Expands Goodwheat™ Mac & Cheese with Nationwide Availability

Arcadia Biosciences, Inc. Announces the Resignation of Laura Pitlik as Chief Marketing Officer

Consensus EPS estimates fall by 31%

Consensus EPS estimates upgraded to US$7.44 loss

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Arcadia Biosciences, Inc. to Report Q3, 2023 Results on Nov 09, 2023

Consensus revenue estimates increase by 13%, EPS downgraded

Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Arcadia Biosciences, Inc. to Report Q2, 2023 Results on Aug 10, 2023

Arcadia Biosciences, Inc. Launches Goodwheat into the Breakfast Category with New Better-For-You Pancake & Waffle Mixes and Single-Serve Quikcakes

First quarter 2023 earnings released: US$10.86 loss per share (vs US$8.09 loss in 1Q 2022)

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

We're Hopeful That Arcadia Biosciences (NASDAQ:RKDA) Will Use Its Cash Wisely

Arcadia Biosciences, Inc. Announces CFO Changes

Consensus forecasts updated

Price target decreased to US$2.50

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Arcadia Biosciences, Inc. to Report Q3, 2022 Results on Nov 10, 2022

Arcadia Biosciences, Inc. to Report Q3, 2022 Results on Nov 10, 2022

Arcadia Biosciences Receives Non-Compliance Letter from Nasdaq

Arcadia Biosciences to raise $5M in securities offering

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

Arcadia Biosciences, Inc. to Report Q2, 2022 Results on Aug 11, 2022

Consensus forecasts updated

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

Arcadia Biosciences, Inc. to Report Q1, 2022 Results on May 12, 2022

Price target decreased to US$3.75

Arcadia Biosciences, Inc., Annual General Meeting, Jun 01, 2022

Consensus revenue estimates fall by 45%

Full year 2021 earnings: EPS and revenues miss analyst expectations

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Arcadia Biosciences, Inc. Announces Executive Changes

Investor sentiment improved over the past week

Price target decreased to US$5.25

Chief Growth Officer Chris Cuvelier has left the company

Arcadia Biosciences: Market Still Unconvinced Of Its Health Offerings

We Think Shareholders Should Be Aware Of Some Factors Beyond Arcadia Biosciences' (NASDAQ:RKDA) Profit

Investor sentiment deteriorated over the past week

Third quarter 2021 earnings released: US$0.098 loss per share (vs US$0.60 loss in 3Q 2020)

Second quarter 2021 earnings released: US$0.24 loss per share (vs US$1.04 loss in 2Q 2020)

Consensus EPS estimates increase to -US$0.81

Price target increased to US$5.75

Consensus revenue estimates increase to US$8.87m

Arcadia Biosciences, Inc. (NasdaqCM:RKDA) acquired Assets of Lief Holdings, LLC and Live Zola, LLC. from Lief Holdings, LLC and Live Zola, LLC for $6.1 million.

Consensus forecasts updated

Full year 2020 earnings released: US$0.47 loss per share (vs US$4.53 loss in FY 2019)

Price target raised to US$7.53

Arcadia Biosciences, Inc. Expands GoodWheat™ Patent Portfolio

Arcadia Biosciences Welcomes Debbie Carosella to Board Of Directors

マネジメント基準チェック /24